68 Ga-CXCR4-targeted PET/CT Outperforms 18 F-FDG PET/CT in FLT3-mutated AML M1 With Granulocytic Sarcoma : Theranostic Insights.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 40644591.
- Also identified by DOI 10.1097/RLU.0000000000006052 and PMC identifier 13132033.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
68 Ga-CXCR4 PET/CT was performed in a patient with acute myeloid leukemia (AML) and granulocytic sarcoma in the left cervical region, who had previously undergone 18 F-FDG PET/CT. Compared with 18 F-FDG PET/CT, 68 Ga-CXCR4 PET/CT revealed a greater number of malignant lymph nodes with more intense uptake in both supradiaphragmatic and infradiaphragmatic regions. Furthermore, markedly increased radiotracer uptake was observed in the bone marrow and spleen compared with FDG. This case underscores the superior sensitivity of 68 Ga-CXCR4 PET/CT in detecting AML infiltration and supports further investigation of CXCR4-targeted imaging and therapeutic approaches in high-risk AML.
Medical subject headings
- Positron Emission Tomography Computed Tomography
- Leukemia, Myeloid, Acute
- Sarcoma, Myeloid
- Fluorodeoxyglucose F18
- Receptors, CXCR4
- fms-Like Tyrosine Kinase 3
- Mutation
- Gallium Radioisotopes
- Theranostic Nanomedicine
- Precision Medicine